Moderna files for authorization of its COVID-19 vaccine in young children in Europe


Shares of Moderna Inc. MRNA, -2.68% said Friday that it asked the European Medicines Agency to authorize its COVID-19 vaccine for use in children between the ages of 6 months and 6 years old. The company also filed for authorization in this age group in the U.S. this week. Moderna separately said Friday that it plans to build an mRNA vaccine manufacturing site in Quebec. Moderna’s stock has declined 44.2% this year, while the broader S&P 500 SPX, -2.06% is down 10.0%.

This article was originally published by Read the original article here.

Previous articleMarket Snapshot: Dow drops 300 points as S&P 500, Nasdaq head for worst month since March 2020
Next articleCoronavirus Update: Mask mandate returns to San Francisco region’s BART system


Please enter your comment!
Please enter your name here